During the last two decades, an immunization program against mealses has recived top priority in Iran; the vaccination campaign started in 1967. Although accura te sta tIStIcs are not available for the preceding years, 150,000 cases of measles werc reported in 1965, and in rural regions more that 10,000 deaths due to measles complications wcrc estimated by the Department of Preventive Medicine of the Iranian Ministry of Health Il 1.
The 60,000 villages affected were scattered throughout the country and contained much of Iran's population of 49 million.
The financial resourccs of the developing world generally do not permit adequate allocations for a normal immunization program. However, in the case of measles in our country, health authorities were ready to provide tinancial support for the control of This major hazard ta children's health.
After the development of the live attenuated measles vaccine by Enders 12J, Iran immediate1y launched mass v3ccination campaigns with imported vaccine. However, the high cost and the vulnerability of the live vaccine constrained expansion of the vaccination program. In 1968 a domestically produced potent and effective vaccine became available, and a program for mass vaccination in rural areas was planned by the Department of Preventive Medicine. The Ministry of Health provided air transport of vaccines to the major cities and refrigerated trucking for transfer of the vaccines to the vaccination centers; installed refrigerators in most of the health centers; made availab1e mobile teams of health personnel trained in mass vaccination for missions to remote rural communities; and maintained a stock of lyophilized live vaccine at -20 C. Whenever possible vaccines were delivered in boxes containing enough dry ice for dispatch to vaccination centers in mountainous regions. Large stocks of disposable syringes and jet in je ct ors were distributed to health centers before performance of operations. ln this report we briefly present sorne details about production of measles vaccine in Iran and the results of our mass campaigns. A short report on the late neurologie complications associated with measles will also be presented. A further-attenuated form of the same strain of virus was isolated by Myamura et al [6J in 1971 after elution of virus from aluminum phosphate. The new strain, ca lied 5FlOO, was also given to us by Chiba Serum Institute. With use of these two strains, between 1968 and 1981 more th an 20 million doses of measles vaccine were produced and lyophilized in multidose vials.
Gelatin-sodium glutamate was used as stabilizer. Each dose of vaccine contained at least 3 log TCID50 virus after lyophilization.
AIK vaccine. AIK-C vaccine lot TV -12 was generously supplied by Dr. S. Makino of the Kitasato Institute in Tokyo. This is a still further attenuated virus derived from the Edmonston virulent strain by Makino et al. [7l. The Edmonston strain was passed 12 times in primary sheep kidney cells at 33 C. The virus was then inoculared into specific pathogen-free chick embryo cultures. Isolated plaques V/ere cloned in chick embryo ceUs, and one clone was se1ected as seed virus for vaccine. This clone was called AIK-C strain. the seventh passage of the AIK-C strain in chick embryo cells was used for vaccine lot 18, 91. The AIK-C vaccine lot TV-12 was directly subcultured (0.1-0.01 TCID50/cell) five times in human diploid ceUs, line MRC-5, in roller bottles at 33 C. A CPE consisting of the appearance of small giant cells was observed at the second and third passages, seven to nine da ys after inoculation. At the fifth passage, the CPE appeared five to six days after inoculation. The maintenance medium was TC199 supplemented with 0.2% gelatin, 50ug of neomycin/ml, and 50 ug of kanamycin/ml at pH 7.6. The medium was changed five days after infection, when the CPE was first observed. Two days later, the fluid was harvested and fresh maintenance medium was added. It was possible to make three to five harvests from each batch. Those harvests having a titer of 4.0 log were pooled and asepticaUy passed through Millipore filters of 5-um pore size or centrifuged 30 min at 2,660 g for removal of cellular debris.
The viral suspension was blended with human alhuminlactose stabilizer, distributed into vials of five or 10 doses, and lyophilized. The viral content per dose was 4.0-4.5 log TCID50 of virus. Four million doses of this vaccine have been used in Iran.
Comparative Field Trials
Since 1968, several field trials have been designed 10 evaluate the domestically manufactured measles vaccines and 10 compare them with other commercial vaccines. In one field trial, 839 susceptible children were divided into five groups. Two groups were immunized with two domestically produced vaccines (Sugiyama and AIK strains); and three groups, with three other live vaccines (Schwarz, Leningrad-16, and Biken-CAM). The clinical responses were not significantly different in the five groups. However, the children who received AIK vaccine ~xhibited milder reactions. Seroconversion rates were 95.5%-100 %, and the mean HAl titers ranged between 5.2 log2 and 6.4 log2 [101. In another trial, 235 children aged 12 months to five years were imrriunized with Sugiyama 5FI00 vaccine or with AIK vaccine. For both vaccines, about 50% of susceptible children showed a rise in temperature of 1 C for about one day. Respiratory disorders such as cough, coryza, and tonsillitis were more severe with Sugiyama 5F100 than with AIK voccine. The seroconversion rates were 94. % and 97.8 for Sugiyama 5F100 and the AIK vaccines, respectively. The mean HAl titer was about 1 10g2 10-wer in children immunized with the AIK vaccine 1111.
Mass Vaccination Campaigns
From 1965 to 1970, the measles vaccines used in Iran were imported derivatives of the Edmonston measles virus (Edmonston B, Schwarz, and Beckenham strains). By 1968, domestically produced vaccines were being used in expanded vaccination programs. The effect of the mass vaccination in reducing m0rbidity and mortality in rural Iran was remarkable (figure 1). At the end of 1971, coverage of only 37% had brought a 56% reduction in morbidity and a dramatic fall in mortality due to measles complications [12J. In 1975 the number of reported case.s was 10% of that in 1966, when mass immunization was first being planned (table 1) . By 1977, both Sugiyama and AIK vaccines were being widely used, and by the end of 1977 an 80% coverage had been achieved. During the past three years, mass immunization has been carried out in the remote districts of the country, especially in the mountainous reg ions.
Age of immunizaton. Until recently the age of immunization against measies in Iran was ni ne ta 12 months. Revaccination with live vaccines was encouraged, especially when children were first immunized before 12 months of age. However, many Jeaths due la measles infection were reported among four-to eight-monthold infants of low socioeconomic strata [131. As previously rcported [14J, most neonates have adequate levels of maternaI antibody to measles virus. By four to six months after birth, this antibody is not longer detectable in the blood of most infants. Evidently, many of these children still have a trace of maternaI antibody that, in combination with cell-mediated immunity, probably protects them against measles infection. On the other hand, sorne children older than four to six months may lack the maternaI antibody to measles and may become victims of the disease before their first birthday. Therefore, a new vaccination scheme has been introduced. l t has been decided to vaccinate infants at six to nine months of age and to revaccina te them at 12 to 15 months of age. Already considerable progress has been achieved in e1imina-ting measles infection in rural communities of Iran. Waves of measles epidemics are no longer observed, as they were before 1970. Deaths due to measles complications in rural areas in 1981 were negligible. A follow-up program J which is of primary importance for avoiding a return to the recent prevalence of mcasles in the rural sectors of Iran, is being planned.
Compllcations of Late Measles
Between 1977 and 1982, in collaboration with a team of neurosurgeons at a children's hospital in Tehran, we studied 100 cases of subacute sclerosing panencephalitis (SSPE). Boys ac-counted for 60% of the patients. Patients were four ta 20 years of age. The levels of HAl antibody in serum and in cerebrospinal fluid of patients, which were measured several times during the course of the disease, were very high in comparison ta those in children immunized against measles. Antibody ta measles virus was also detected in the saliva of aIl patients with SSPE at various stages of the disease. The relatively low titer of antibody in their saliva may indicate that antibody may have leaked from the circulating system into the saliva. But intense fluorescent staining of the ceUs lining the salivary ducts ~uggest ed the presence of viral antigen on the glandular ceU membranes U5J. Cocultivation of saliva gland biopsies yielded no virus after 10 passages. However, in three of seven brain biopsies, it was possible ta isolate ceU-associated measles-like virus by cocultivatian with Vero ceUs f161.
